SHANGHAI, March 29, 2017 /PRNewswire/ -- WuXi Biologics, a
leading open-access R&D capability and technology platform
company dedicated to biologics and a WuXi AppTec Affiliate, today
announced that it had received the 2017 Asia-Pacific Best
Bioprocessing Excellence Award from IMAPAC, a leading consulting
firm.
Asia-Pacific Bioprocessing Excellence Awards aims to recognize
outstanding leaders and trend-setters of today, and inspire
innovators of tomorrow. Featuring top bioprocessing and
biomanufacturing experts in the industry, along with the latest
advances in technologies and best practices in manufacturing, WuXi
Biologics has been recognized for its outstanding performance that
facilitating biomanufacturing excellence at enhanced speed, reduced
cost and superior quality.
As an open-access biologics technology platform, WuXi Biologics
opened its state-of-the-art biologics manufacturing facilities at
Wuxi city in 2012, which is the first in China that
met cGMP standards of the United
States, the European Union, and China. In 2015,
WuXi began construction of world's largest mammalian cell culture
manufacturing facility using disposable bioreactors with a planned
manufacturing capacity of 30000L, and completed construction of
Asia's largest perfusion biologics
manufacturing facility using disposable bioreactors in 2016,
offering end-to-end solution to our worldwide customers and
partners.
"WuXi Biologics is honored to be recognized by IMAPAC," said Dr.
Chris Chen, CEO of WuXi Biologics,
"The award truly reflects all of the efforts we have put forth to
provide our customers with high-quality and best-in-class service
to help accelerate biologics development from concept to
commercialization."
About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical,
biopharmaceutical, and medical device open-access capability and
technology platform company with global operations. As an
innovation-driven and customer-focused company, WuXi AppTec
provides a broad and integrated portfolio of services to help our
worldwide customers and partners shorten the discovery and
development time and lower the cost of drug and medical device
R&D through cost-effective and efficient solutions. With its
industry-leading capabilities in small molecule R&D and
manufacturing, biologics R&D and manufacturing, cell therapy
and gene therapy R&D and manufacturing, medical device testing,
and molecular testing and genomics, WuXi platform is enabling
nearly 3,000 innovative collaborators from more than 30 countries
to bring innovative healthcare products to patients, and to fulfill
WuXi's dream that "every drug can be made and every disease can be
treated." Please visit http://www.wuxiapptec.com
About WuXi Biologics
WuXi Biologics, a WuXi AppTec Affiliate, is a leading
open-access technology capability and technology platform to enable
anyone and any company to develop biologics. WuXi Biologics
provides our worldwide clients with the necessary expertise,
quality and capacities to develop biologic drugs from concept to
commercialization. Along with our WuXi AppTec affiliates, we
provide the world with the ONE true single-source approach that
saves our clients critical time and money. Our company history and
achievements demonstrate our commitment to providing a truly
ONE-stop service offering and value proposition to our global
clients. For more information on WuXi's Biologics services, please
visit:http://www.wuxibiologics.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/wuxi-biologics-receives-asia-pacific-best-bioprocessing-excellence-award-from-imapac-300431576.html
SOURCE WuXi AppTec